When the Pandemic Ends and the Endemic Continues: The Evolving Role of Monoclonal Antibody Therapies in the Fight Against COVID-19

This presentation explores monoclonal antibody treatments for high-risk patients with COVID-19. Join Dr. Michael Anderson, senior advisor at the Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response for an up-to-the minute review on these expanding therapies and the role they will continue to play as the COVID-19 pandemic shifts to a national epidemic.


Learning Objectives


At the conclusion of this activity, participants should be able to: 

  • Recognize the role that monoclonal therapies play and the critical treatment timing window
  • Differentiate among the available therapies based on EUA data
  • Work collaboratively across the healthcare continuum of care to help ensure all appropriate patients can have access to the therapies, including those therapies secured by the federal government
  • Appreciate the need to identify patients at greatest risk, particularly those in underserved communities or minority groups